33-Breast metastatic trastuzumab three weekly

In 2006, trastuzumab plus chemotherapy was approved to treat patients after their HER2-overexpressing breast tumors were surgically removed

For treating certain types of breast, stomach or esophagus cancers, and othersTrastuzumab is available as a biosimilar medication See our biosimilar pamphlet

trastuzumab On April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo,

trastuzumab For women with HER2-positive metastatic breast cancer, trastuzumab may be given on its own or with other treatments Treatment with trastuzumab